Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000005

Drug Information
SynonymsPDGF TK antagonist; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; AC1NS62J; SU 11248; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; NSC736511; SU-11248J; 326914-13-0; NSC750690; K00588a; Su-011248; Sunitinib; SU-12662; KS-5022; CHEMBL535; UNII-V99T50803M; Sunitanib; 557795-19-4; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; NCGC00164631-01; SU11248; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)- (5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; LS-187023; DB01268; I01-1229; CID5329102; SU-11248; CHEBI:38940; sunitinibum; DB07417; LS-187648; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; FT-0083556; Sutent; D08552; Sunitinib (free base); Sunitinib (INN); EN002687; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-
Trade NameSutent
CompanyPfizer (Sugen)
IndicationAdvanced renal cell carcinoma
[ICD9: 189   ICD10: C64]
Launched    [1]
Advanced renal cell carcinoma
[ICD9: 189   ICD10: C64]
Phase II    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESCCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C    
Isomeric SMILESCCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 557795-19-4
PubChem Compound IDCID 5329102.
PubChem Substance IDSID 3889616.
SuperDrug ATC IDL01XE04
TargetFL cytokine receptorInhibitor[2][3][4][5]
FL cytokine receptorMultitarget[2][3][4][5]
Mast/stem cell growth factor receptorInhibitor[2][3][4][5]
Mast/stem cell growth factor receptorMultitarget[2][3][4][5]
Platelet-derived growth factor receptorInhibitor[2][3][4][5]
Platelet-derived growth factor receptorMultitarget[2][3][4][5]
Vascular endothelial growth factor receptor 2Inhibitor[2][3][4][5]
Vascular endothelial growth factor receptor 2Multitarget[2][3][4][5]
Ref 1Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. To Reference
Ref 2FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat. 2009 Jun;12(3):81-9. Epub 2009 May 20. To Reference
Ref 3FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res. 2009 Apr 1;69(7):3032-41. Epub 2009 Mar 24. To Reference
Ref 4A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference
Ref 5Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. Epub 2006 Nov 28. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543